RTX-224 Monotherapy in Patients With Solid Tumors
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT05219578 |
|
Recruitment Status :
Terminated
(The Sponsor terminated study after dosing 2 dose groups (7 pts) and closed trial on 11/30/22. RTX-224 was well-tolerated with no DLTs, no related deaths, SAEs or Gr. 3/4 AEs and cleared rapidly (w/in 10 min).)
First Posted : February 2, 2022
Last Update Posted : December 9, 2022
|
Sponsor:
Rubius Therapeutics
Information provided by (Responsible Party):
Rubius Therapeutics
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Terminated |
|---|---|
| Actual Primary Completion Date : | November 30, 2022 |
| Actual Study Completion Date : | November 30, 2022 |